PREDICTION ON VACCINE POTENCY & INTRANASAL APPLICATION VALIDATED

Synergia Foundation was first to evaluate the COVID-19 vaccines’ response metric and challenged the claimed-90 percent protective efficacy of Covid vaccine (Oxford/AstraZeneca).

Since the advent of the COVID pandemic in 2019, we have been forecasting that the nasal vaccine capable of producing ‘sterilizing immunity’ is the most effective disease control tool.

The Synergia Foundation in collaboration with Oxford University’s Blavatnik School of Government organized a round table on the “Global Race for COVID-19 Vaccines” in November 2020. Distinguished speakers included Suerie Moon- Research Director, Harvard Global Health Institute, John Arne Rottingen – CEO of the Research Council of Norway, Jo Wolff -Professor of Values and the Public Policy University of Oxford, Prof.K. VijayRaghavan-Principal Scientific Adviser Govt of India, Gifty Immanuel Chief Medical Officer, Synergia and Tobby Simon-President Synergia Foundation. The key objective of the roundtable was to Chart an international roadmap for the production and delivery of COVID-19 vaccines.

The Synergia foundation has been consistently advocating the need for modest claims on vaccine metrics, efficacy, and protection. This is to ensure that Governments and Citizens around the globe are not misguided about a vaccine based on claims by corporations and institutes.

At the round table, Synergia’s Dr. Immanuel opined that “monitoring for long-term reactions against vaccination will need to continue and efficacy rates for existing candidate vaccines – reported to be up to 95,97 percent in the case of mRNA vaccines – may not fare so well after a period of months”.

He further added that the Hepatitis B vaccine currently has an efficacy rate of around 80 percent, while influenza is more like 60 percent. That could ensure booster jabs are needed year after year, leading the virus to mutate as “the moment you put viruses under selection pressure, it is bound to show some resistance”. Similarly, Tobby Simon, founder and president of the foundation stated that “there is a need to understand that efficacy claims can drop over a period and claims of 90 percent and above are unreliable. A rushed decision could have dangerous repercussions”. Following the deliberations, Global vaccine makers and researchers insisted to state a modest figure of the efficacy numbers.

19 Nov, 2020 10:46 PM

Covid 19 coronavirus: Virus ‘will fight back’ against vaccination, expert warns following Oxford University, AstraZeneca results

An infectious diseases expert has warned the “virus will fight back” against efforts to secure a Covid-19 vaccination, ensuring that having proven protection against the disease is not the end of the story.

Dr Gifty Immanuel, an infectious disease specialist from Bangalore, India, said while the incredible cooperation to secure viable vaccine candidates in under 12 months is “heartwarming” there are “certain pitfalls” ahead that cannot be overlooked.

Intranasal Vaccine

Dr Immanuel raised the issue of the recent mink cull in Denmark after the animal was found to create a much more potent strain of the virus, saying this kind of zoonotic event could not be ruled out again and “could completely destroy” what the world had been working to achieve.

Since the advent of the COVID pandemic in 2019, we have been forecasting that the nasal vaccine capable of producing ‘sterilizing immunity’ is the most effective disease control tool. Intranasal immunization is excellent for mass immunization, it is needless and is easy to administer without a steep learning curve.

It stimulates mucosal and systemic immunity, better protecting against respiratory pathogens. It produces the antibody IgA less produced in the IM vaccine. The intranasal technology produces a higher quantum of IgA, IgG, and IgM- all three antibodies. This can result in the prevention of transmission between people, eventually resulting in the eradication of the disease.